All Oncology News

The FDA has approved acalabrutinib plus venetoclax for the treatment of adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

At the OncLive National Fellows Forum during SABCS 2025, notable data were presented on ethnic differences in early HR+ breast cancer and genomic insights in women post partum.

Dual CD19- and CD20-targeting CAR T-cell therapy was effective and had a unique safety profile in patients with relapsed/refractory CLL.

Mayo Clinic researchers identified a previously unrecognized way lung tumors weaken the immune system.

Deirdre J. Cohen, MD, MS, discusses key considerations when navigating first-line chemotherapy selection in metastatic pancreatic cancer.

Mario Sznol, MD, discusses how the field is balancing dual checkpoint blockade and novel combinations in melanoma, plus unmet needs and emerging strategies.

Obinutuzumab in combination with venetoclax yielded responses in chronic lymphocytic leukemia and small lymphocytic leukemia.

David Rimm, MD, PhD, discusses ways that the use of ADCs in breast cancer might adapt to reflect emerging categories of detectable HER2 expression levels.

The European Commission has approved nogapendekin alfa inbakicept plus BCG in BCG-unresponsive NMIBC with CIS, with or without papillary tumors.

A WVU Cancer Institute team investigated the efficacy of subcutaneous blinatumomab in treating one of the rarest and most aggressive forms of leukemia.

Jason Aboudi Mouabbi, MD, discusses challenges associated with diagnosing lobular breast cancer and the promising predictive value of FES-PET/CT imaging.

An ML-NMR analysis associated zanubrutinib with PFS improvements vs ibrutinib or acalabrutinib in relapsed/refractory chronic lymphocytic leukemia.

The FDA accepted an NDA for iberdomide plus daratumumab/dexamethasone in relapsed/refractory multiple myeloma, supported by MRD benefit in EXCALIBER-RRMM.

Topline data from cohort 3 of BREAKWATER showed improvements in key secondary end points of PFS and OS in previously treated, BRAF V600E–mutant mCRC.

An NDA for tirabrutinib in relapsed or refractory primary central nervous system lymphoma has been accepted for review by the FDA.

At The University of Texas MD Anderson Cancer Center, research breakthroughs are made through collaboration between leading clinicians and scientists.

The FDA approved a monthly dosing schedule of amivantamab and hyaluronidase for the first-line treatment of patients with EGFR-mutated, advanced NSCLC.

Real-world data suggest CD20 bispecific antibodies show activity after CD19 CAR T in mantle cell lymphoma, though durability of response remains unclear.

Dana-Farber Cancer Institute will host the Fifth Transatlantic Exchange in Oncology, bringing together leading cancer researchers and clinicians.

Improved EFS was seen when selpercatinib was administered as adjuvant therapy vs placebo in early-stage RET fusion–positive NSCLC.

Alfonso Molina, MD, MPH, discusses a phase 1 trial evaluating Orca-T with allogeneic CAR T-cell therapy in high-risk B-cell acute lymphoblastic leukemia.

The top 5 OncLive TV videos of the week cover insights in kidney cancer, myeloproliferative neoplasms, breast cancer, systemic mastocytosis, and pancreatic cancer.

The FDA approves pembrolizumab regimen in select ovarian cancer, the agency clears Optune Pax for pancreatic cancer, and more this week.

David Rimm, MD, PhD, discusses whether ADCs should be considered similar to targeted therapy, or whether this class of agents is more akin to chemotherapy.

Experts weigh in on combination approaches and how evolving first-line therapy affects second-line sequencing strategies in advanced EGFR-mutant NSCLC.

A group of researchers from the University of Miami sought to understand why many clinical trials in head and neck cancers fail.

Benjamin A. Weinberg, MD, FACP, discusses the specific therapeutic goals and challenges of third-line metastatic colorectal cancer management.

Research showed that an oncolytic virus could prolong survival in patients with glioblastoma.

Bladder cancer experts share the most anticipated abstracts expected at the 2026 Genitourinary Cancers Symposium.

Deepti Radia, MBBS, BSc, MRCPI, FRCPath, MSc Med Ed, discusses 4-year data from the PATHFINDER trial of avapritinib in advanced systemic mastocytosis.